No difference on survival for patients with metastatic castration-resistant prostate cancer treated with apalutamide-abiraterone combination therapy
Prolonged radiologically progression-free survival did not transfer into better overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated with two androgen-targeted drugs instead of one.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
